NEW YORK, June 30, 2014—Kantar Health, a leading global healthcare consulting firm, today announced it will host its 10th annual seminar in Tokyo highlighting the implications of recent drug approvals and clinical results in the oncology competitive landscape for pharmaceutical companies. The seminar is presented in conjunction with Synix Inc., Kantar Health’s partner in Japan.
The seminar will take place at Conference Square M+ in Tokyo on Thursday, July 10, and will be led by Tatiana Spicakova, Ph.D., Consultant, Clinical and Scientific Assessment, and Richard Wagner, Ph.D., Vice President, Oncology Commercial Strategies. The session will cover the drug development and treatment trends reported during recent oncology conferences.
- Gastrointestinal Cancers (Colorectal and Gastric)
- Discussion of recent developments to determine best choice of therapy in first-line colorectal cancer (CALGB 80405) and in relapsed/refractory colorectal and gastric cancers (Cyramza (ramucirumab, Eli Lilly), Lonsurf (TAS-102, Taiho))
- Breast Cancer
- Discussion of recent data and market impact associated with development in hormone receptor-positive breast cancer, as well as ongoing advances in triple-negative disease
- Prostate Cancer
- A review of the current treatment landscape and new early-phase data that could have an impact on this market in the future
- A review of pivotal new data for BRAF inhibitors and PD-1/PD-L1 inhibitors and a discussion of the future evolution of treatment in this disease
- Non-Small Cell Lung Cancer
- A discussion of recent developments in relapsed/refractory disease (Cyramza (necitumumab, Eli Lilly), pembrolizumab (Merck)) and next-generation inhibitors in biomarker subpopulations (EGFR, ALK)
- Discussion of new data for PD-1/PD-L1 inhibitors and other immunotherapeutics in development, with a review of development strategies
- Chronic Lymphocytic Leukemia
- Discussion of recent pivotal data (Imbruvica (ibrutinib, Pharmacyclics/Janssen), idelalisib (Gilead), Arzerra (ofatumumab, GSK/Genmab), Gazyva (obinutuzumab, Genentech/Roche)) and the rapidly changing standard of care in this disease
- Novel Mechanisms of Action
- A brief highlight of some of the upcoming mechanisms of action in development that could have a large clinical impact, including inhibitors of CDK, PARP, stem cell pathway and novel combination strategies
To register for this seminar, please visit http://www.synix.co.jp or contact Hiroe Kujirai at email@example.com.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.